𝔖 Bobbio Scriptorium
✦   LIBER   ✦

743 The majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS®] sustain responses 2 years post-treatment

✍ Scribed by P. Marcellin; E. Bonino; G.K.K. Lau; P. Farci; C. Yurdaydin; T. Piratvisuth; R. Jin; S. Gurel; S. Hadziyannis; Z.-M. Lu; M. Popescu


Book ID
117375019
Publisher
Elsevier Science
Year
2006
Tongue
English
Weight
115 KB
Volume
44
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES